What happened with ARMP today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Armata Pharmaceuticals is developing treatments for antibiotic-resistant and other difficult-to-treat bacterial infections. It uses viruses that infect and kill specific bacteria, called bacteriophages, and develops and manufactures these into drug candidates for clinical testing. Its AP-SA02 candidate targets Staphylococcus aureus infections, including bloodstream infections.
Armata has no commercial product sales. Its revenue comes from the MTEC government-funded award, which covers a share of AP-SA02’s clinical development costs. Its research and trials depend heavily on government grants, and it also needs additional capital to continue operations and development. To earn revenue from drug sales, Armata must complete development and obtain marketing approval; it cannot market its candidates in the United States without FDA approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Armata’s results hinge on clinical success and funding for its phage therapies; Locus Biosciences and Intralytix are additional competitors to watch beyond this list.
Armata depends on controlling shareholder Innoviva, Inc. to finance its bacteria-killing virus treatments, giving Innoviva direct exposure to their success alongside its own infectious-disease medicines and respiratory-drug royalties. Watch Innoviva’s funding commitments: Armata’s amended credit agreements with its subsidiary now mature on June 1, 2027.
Tessera Defense and Homeland Security Inc. appears here for the supplied BiomX business, whose mixtures of bacteria-killing viruses compete with Armata’s phage therapies for bacterial infections. BiomX’s ability to advance those treatments is now the key watchpoint: its core operating subsidiary entered insolvency proceedings in Israel in December 2025, leaving limited ongoing operations and little ability to advance programs as planned without additional resources.
Fed Interest Rate Decision
For Armata, the Fed’s decision on its benchmark interest rate matters because higher rates can make refinancing its 14% term loans or obtaining additional funding harder and more costly, though the stated loan rates are fixed and do not change directly with the Fed’s rate.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s rate is above the estimate, higher borrowing costs across the economy could make refinancing or new funding harder and more expensive for Armata, while interest on its stated fixed-rate loans would not change directly.
If it comes in below expectations
If the Fed’s rate is below the estimate, lower borrowing costs across the economy could ease the cost and availability pressures Armata faces when refinancing or seeking new funding, while interest on its stated fixed-rate loans would not change directly.
Innoviva, Inc. earningsINVA
Innoviva’s report can show whether Armata’s controlling shareholder and lender has the capacity and willingness to keep financing the company’s phage-drug development.
Read Innoviva’s disclosures about its resources and support for Armata alongside Armata’s ongoing development needs and loan arrangements. If Innoviva indicates it has both the capacity and willingness to provide support, Armata has another funding channel for clinical development. If Innoviva’s resources are constrained or further support is absent, Armata must find other capital, putting research and trials under pressure.
Armata Pharmaceuticals, Inc. earningsThis company
Armata’s report will show whether its MTEC award is still sharing AP-SA02 clinical-development costs as the company uses cash to advance its phage-drug pipeline.
Read MTEC award revenue alongside research spending and operating cash use. Continued award revenue with contained spending and cash use would show the grant is still sharing AP-SA02 development costs and that available funds are better able to support research. If award revenue fades while cash use stays high, Armata will need other capital to keep trials and manufacturing work moving, putting programs at risk.
Tessera Defense and Homeland Security Inc. earningsHLSQ
Tessera’s report can show whether the BiomX phage programs it represents have resources to advance, indicating whether a competitor to Armata is still developing treatments for bacterial infections.
Look for whether Tessera’s disclosures show the BiomX programs resuming or advancing with resources, and compare that with Armata’s own clinical development. If those programs are funded and moving forward, Armata still faces another set of phage treatments for bacterial infections. If they remain stalled, near-term pressure from those programs is lower, but that does not show that Armata’s treatments work or are succeeding in development.
